Rule, S., & Witzens-Harig, M. (2018). Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia, 32(8), . https://doi.org/10.1038/s41375-018-0023-2
Chicago-Zitierstil (17. Ausg.)Rule, Simon, und Mathias Witzens-Harig. "Ibrutinib Versus Temsirolimus: 3-year Follow-up of Patients with Previously Treated Mantle Cell Lymphoma from the Phase 3, International, Randomized, Open-label RAY Study." Leukemia 32, no. 8 (2018). https://doi.org/10.1038/s41375-018-0023-2.
MLA-Zitierstil (9. Ausg.)Rule, Simon, und Mathias Witzens-Harig. "Ibrutinib Versus Temsirolimus: 3-year Follow-up of Patients with Previously Treated Mantle Cell Lymphoma from the Phase 3, International, Randomized, Open-label RAY Study." Leukemia, vol. 32, no. 8, 2018, https://doi.org/10.1038/s41375-018-0023-2.